« Return to News | Drug Sponsors

AstraZeneca, IMS Health team up to use real-world evidence

Wednesday, January 11, 2012 03:40 PM

AstraZeneca has entered into a three-year collaboration agreement with IMS Health, a leading provider of healthcare information, services and technology, to further the use of real-world evidence based on observational and retrospective studies.

The pair hopes the information will provide a deeper insight into how medicines already on the market are working on real-world settings across Europe, illuminating unmet needs in the current standard of care and treatment patterns across a number of therapeutic areas, with an emphasis on chronic illnesses.

"Our collaboration with IMS is a key milestone in our commitment to understand the impact of our medicines in the real world, beyond what we see in controlled clinical trials,” said Martin Mackay, president of R&D for AstraZeneca. “This insight will help us and healthcare decision-makers to improve the treatment of disease and ensure effective use of medicines to minimize the burden on individuals and healthcare budgets."

The partnership will give AstraZeneca access to pre-existing anonymized electronic health record, which includes clinical outcome, economic and treatment pattern data. The companies also plan to jointly develop a customized research and data analysis platform.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.